Atorvastatin MS

Quick links to important sections

Atorvastatin MS

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atorvastatin MS

Quick Facts

Property Description
Active Ingredient Atorvastatin (as calcium trihydrate)
Form Film-coated tablet
Pharmacological Class Statin (HMG-CoA reductase inhibitor)
Common Use Management of high blood lipids (cholesterol)
Origin Synthetic compound

What Type of Medicine is Atorvastatin MS?

Atorvastatin MS is a prescription-only pharmaceutical preparation classified as a statin, belonging to the broader pharmacological category of HMG-CoA reductase inhibitors. This drug entity is chemically recognized for its targeted lipid-lowering capabilities. Its primary function is to act as an antihyperlipidemic agent, managing elevated levels of fats in the bloodstream. The active substance, Atorvastatin, is a distinct synthetic compound derived as a pyrrole derivative. Atorvastatin is recognized as a core therapeutic agent for reducing cardiovascular risk factors.

Composition, Form, and General Therapeutic Purpose

The active component in Atorvastatin MS is the compound Atorvastatin, supplied as the calcium trihydrate salt, formulated for oral administration in the physical form of a solid, film-coated tablet. Atorvastatin is a potent statin agent, characterized by its ability to achieve significant reductions in Low-Density Lipoprotein Cholesterol (LDL-C) levels. This means its core therapeutic purpose is to reduce circulating LDL-C—or "bad cholesterol"—which is crucial for managing the lipid profile. Its use in scenarios involving primary hypercholesterolemia serves the broad public health goal of mitigating the long-term cardiovascular risk associated with uncontrolled dyslipidemia.

Regulatory References

  1. Atorvastatin - NCBI Bookshelf
  2. Atorvastatin - WHO Essential Medicines List

What side effects are possible with Atorvastatin MS?

Possible Side Effects and Safety Information

The safety profile of Atorvastatin MS is defined by regulatory documents, classifying possible adverse reactions by frequency and the body system affected. These classifications establish the spectrum of effects, from those commonly reported to rare, serious events. Adverse reactions are grouped by System-Organ Class (SOC), including the Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.

Frequency and Common Effects

Side effects are formally classified based on incidence rates observed in clinical trials, using tiers such as Common (occurring in 1 to 10 out of 100 people) and Uncommon (occurring in 1 to 10 out of 1,000 people). Common effects include nasopharyngitis, headache, myalgia (muscle pain), arthralgia (joint pain), back pain, and certain gastrointestinal issues like nausea, diarrhea, or constipation.

Serious Reactions and Safety Constraints

Specific rare events are documented as serious adverse reactions. These include rhabdomyolysis, which is severe muscle breakdown, and hepatic failure (liver failure). The risk for muscle-related effects is formally documented as being dose-dependent. Reports of Immune-Mediated Necrotizing Myopathy (IMNM) have also been noted with an unknown frequency.

Administration is formally contraindicated in patients with active liver disease or unexplained persistent elevations in liver enzymes, as well as during pregnancy and lactation. Certain patient groups, such as geriatric patients and those with renal impairment, have specific safety notes regarding the increased risk of certain muscle effects.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the official, label-based regulatory guidance for managing overdosage or severe adverse manifestations associated with high systemic exposure to Atorvastatin MS.

Overdose Scope

Feature Official Regulatory Statement
Documented Overdose Presentations Presentation is often asymptomatic; the primary documented risk is myopathy progressing to rhabdomyolysis, associated with markedly elevated Creatine Kinase (CK) levels.
Physiological Systems Affected Musculoskeletal system (Rhabdomyolysis); Renal system (Acute renal failure secondary to myoglobinuria); and Hepatobiliary system (Fatal and non-fatal hepatic failure).
Population-Specific Overdose Notes Advanced age (65 years) and underlying renal impairment are cited as factors predisposing patients to the most severe skeletal muscle effects.

Required Emergency Actions

Classification Aspect Official Regulatory Statement
Immediate Medical Help Required When Patients must seek medical attention immediately upon observing unexplained and/or persistent muscle pain, tenderness, or weakness, particularly if accompanied by fever or malaise.
Antidote/Clearance Constraints No specific treatment or antidote is known for Atorvastatin overdosage. Furthermore, hemodialysis is explicitly stated as not being expected to significantly enhance clearance due to the extensive binding of the drug to plasma proteins.

Official Overdose Statements

  • Overdosage management must be symptomatic and supportive, with measures instituted as required by the patient's clinical status.
  • The most severe outcome noted in regulatory documents is the risk of rhabdomyolysis leading to acute renal failure.

Regulatory guidance establishes that the management of Atorvastatin overdosage is entirely symptom-driven, focusing on supportive care given the lack of a known antidote and the ineffectiveness of forced clearance methods. The profile mandates that patients report specific muscle symptoms immediately, as these are the crucial signs dictating urgent medical evaluation.

Therapeutic Uses of Atorvastatin MS

What Atorvastatin MS Treats: Main Uses and Benefits

The use of Atorvastatin MS is relevant to manage symptoms related to systemic imbalance and supports the management of cardiovascular risk over time. It is considered relevant for patients with elevated cholesterol, including primary hypercholesterolemia, mixed dyslipidemia, and the inherited condition familial hypercholesterolemia.

This medication is fundamentally applied in preventative contexts, either for primary prevention (reducing risk before a first event) or secondary prevention (reducing risk after a prior event). A key therapeutic benefit is its relevance in the management of risk for severe acute events, such as heart attack (myocardial infarction) and stroke. By addressing this systemic imbalance, it assists with functional stability related to vascular health.

“The therapeutic benefit of managing these blood lipid abnormalities supports general well-being during symptomatic phases related to vascular disease.”

Quick Fact: Focus on Cardiovascular Risk Management

Therapeutic Focus Benefit to Patient
Asymptomatic Lipid Abnormalities Contributes to easing the systemic symptom load.
Risk Factors for Acute Events Supports the management of future heart attack and stroke risk.
High-Risk Scenarios (e.g., T2D) Assists with maintaining functional stability related to vascular health.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Atorvastatin MS eligibility is strictly defined by government regulatory agencies, establishing both absolute contraindications and conditional use populations.

Populations Excluded from Use

The medicine is contraindicated and must not be used in specific populations. This includes individuals with active liver disease or unexplained persistent elevations of liver enzymes. Use is also formally prohibited for women who are pregnant or breastfeeding due to potential risks, and for any patient with a known hypersensitivity to atorvastatin.

Eligible and Restricted Use Groups

The medicine is generally approved for use in adults for managing high blood lipid levels. In the pediatric population, eligibility is restricted to children and adolescents aged mathbf10 years and older specifically for treating inherited forms of high cholesterol. While generally acceptable, use requires special caution for patients with a history of liver problems, those who consume substantial alcohol, and those with pre-existing risk factors for muscle issues, such as uncontrolled hypothyroidism or advanced age (ge 65). Renal impairment alone does not require a dosage change but is also a risk factor for myopathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope: The official regulatory interaction profile for Atorvastatin MS is primarily defined by pharmacokinetic and pharmacodynamic mechanisms. Pharmacokinetic interactions involve the CYP3A4 enzyme system and drug transporter proteins such as OATP1B1, BCRP, and P-gp. Inhibition of these systems by medicines, including certain antibiotics and antiviral agents, can significantly increase Atorvastatin plasma concentrations (exposure). Pharmacodynamic interactions concern the additive risk of myopathy and rhabdomyolysis, a risk officially documented with co-administration of Fibric Acid Derivatives and Colchicine.

Interaction Restrictions: Regulatory documents stipulate formal contraindications for co-administration with substances such as Cyclosporine, Systemic Fusidic Acid, and the Hepatitis C regimen Glecaprevir/Pibrentasvir. These constraints are a direct result of the severe risk of increased exposure or additive toxicity. Specific timing rules are mandated: Atorvastatin must be discontinued during and for 7 days after stopping Systemic Fusidic Acid. Conversely, Rifampin requires simultaneous co-administration to mitigate reduced Atorvastatin plasma levels. Interactions with consumption items include the constraint on large quantities of grapefruit juice and the documented risk associated with substantial alcohol consumption. Increased interaction risk is also officially noted for geriatric patients and those with renal impairment.


The structure of the interaction profile strictly outlines which substances alter Atorvastatin exposure or increase toxicity risk according to regulatory evidence, forming the basis for mandated restrictions and administration requirements found in official labeling.

Mechanism of Action

Enzyme Inhibition and Enhanced LDL Clearance

Atorvastatin is a selective, competitive inhibitor of HMG-CoA Reductase, the rate-limiting enzyme in the liver responsible for cholesterol synthesis. Blocking this enzyme causes liver cells to deplete their internal cholesterol reserves, initiating a regulatory cascade. This depletion triggers the upregulation of LDL receptors on the liver cell surface, which enhances the physiological process of actively clearing LDL particles from the bloodstream.

Vascular Signal Pathway Modulation (Pleiotropic Effects)

Beyond its action on lipid synthesis, Atorvastatin modulates signaling pathways in blood vessel walls. This effect results from the reduction of downstream isoprenoid molecules, which prevents the proper function of certain small G-proteins (Rho, Rac). This mechanism contributes to the modulation of endothelial function by increasing the bioavailability of Nitric Oxide ( NO), which regulates vascular tone and modulates the expression of inflammatory mediators in the vessel wall.

Mechanistic Constraints

The drug's core action is biologically constrained by the availability of functional LDL receptors; in conditions where functional LDL receptors are absent, such as Homozygous Familial Hypercholesterolemia (, HoFH), the mechanism of increased clearance is functionally reduced.

Dosage and Administration Information

Atorvastatin MS is administered via the oral route as a film-coated tablet, intended for once-daily intake as part of a long-term therapeutic protocol. The tablet may be taken at any time of the day, and ingestion is permissible with or without food.

Official Dosing Regimens

For adults, the usual starting dose is 10 mg or 20 mg once daily, although a 40 mg starting dose may be used for patients requiring a reduction in low-density lipoprotein cholesterol (LDL-C) greater than 45%. The overall dosage range is 10 mg to 80 mg once daily, with 80 mg being the maximum daily dose. Dose adjustments are made based on the patient's response and therapeutic goals, but must occur at intervals of four weeks or more.

Use in Specific Populations

No dose adjustment is generally required for patients with renal impairment. For children and adolescents aged 10 years and older with Heterozygous Familial Hypercholesterolemia (HeFH), the recommended maximum dose is 20 mg once daily.

Missed Dose Guidance

If a dose is missed, it should be taken as soon as it is remembered on the same day. However, if the full day has passed, the missed dose should be skipped entirely, and the regular dosing schedule should be resumed the following day. Double dosing to make up for a missed dose is not recommended.

Recent Clinical Evidence

Research evidence / Overview of studies for Atorvastatin MS

Studies Evaluating Primary Prevention of Cardiovascular Events

The research on Atorvastatin MS includes large, multi-center studies known as Randomized Controlled Trials (RCTs). This type of research was applied in studies examining adults who had established cardiovascular risk factors, such as high blood pressure or Type 2 Diabetes, but who had not yet experienced a heart attack or stroke.

These trials were conducted to monitor the incidence of major cardiovascular events (MACE), including nonfatal heart attack and stroke, over multi-year periods. Researchers also tracked changes in certain blood markers, such as Low-Density Lipoprotein Cholesterol (LDL-C). The research describes patterns observed in these large studies related to cardiovascular events and lipid biomarker measurements in the populations observed.


Studies Evaluating Secondary Prevention of Cardiovascular Events

Research also explored the medicine was studied for secondary prevention, which involved adults who had already experienced a cardiovascular event, such as those with stable Coronary Heart Disease (CHD) or those who recently had Acute Coronary Syndromes. Again, large-scale Randomized Controlled Trials were conducted to monitor the recurrence of serious events.

Studies monitored outcomes reflecting episodic or acute changes, specifically tracking the occurrence of heart attack or stroke. The research also described patterns related to measurements of lipid markers when comparing different daily amounts of the medicine.


Studies Evaluating Hypercholesterolemia and Dyslipidemia

Research examined the medicine for elevated cholesterol and mixed dyslipidemia. The evidence consists of Randomized Controlled Trials that were generally of shorter duration than the large prevention studies. This research examined outcomes linked to temporary physiological imbalance by monitoring lipid biomarkers like LDL-C (the main focus) and Total Cholesterol.

Research describes short-term changes in lipid biomarker levels over observation periods typically lasting up to one year. A key difference in this area of research is that the studies focused primarily on these surrogate endpoints (such as lipid measurements).


Studies Exploring Familial Hypercholesterolemia

Atorvastatin MS was studied for use in patients with Heterozygous Familial Hypercholesterolemia (HeFH), an inherited condition causing high cholesterol. The research is based on Controlled Trials and Observational Studies, exploring changes in lipid biomarkers in both adults and specific groups of pediatric patients (children as young as 10 years old). Follow-up durations for children typically spanned up to approximately 1.5 years.


Research Gaps and Areas of Uncertainty

The research base includes numerous large studies, but certain gaps and limitations are noted. The evidence for very long-term outcomes extending many years beyond the typical trial length are areas where data are still emerging. Additionally, subgroup findings are uncertain when looking at groups where patient-reported experiences or factors outside of the study design were observed, as the results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Familial hypercholesterolaemia: identification and management (NICE Clinical Guideline CG71)

Frequently Asked Questions (FAQ)

Common questions about Atorvastatin MS (FAQ)


Q: Does Atorvastatin MS require a prescription?

A: Yes, according to the official product information, Atorvastatin is formally classified as a prescription-only pharmaceutical preparation. It is not available for purchase over the counter.


Q: Is Atorvastatin MS the same kind of medicine as simvastatin?

A: According to official product information, both Atorvastatin and simvastatin belong to the same pharmacological class, known as statins. They share the same fundamental mechanism of inhibiting the HMG-CoA reductase enzyme to lower cholesterol. However, they are distinct synthetic compounds that differ in their chemical structure and relative strength (potency).


Q: Can Atorvastatin MS cause muscle pain or stiffness?

A: Regulatory documents confirm that muscle pain, known as myalgia, is a commonly reported side effect, occurring in 1 to 10 out of every 100 people. Reports of muscle stiffness have also been documented. In rare cases, more severe muscle issues, including a condition called rhabdomyolysis (severe muscle breakdown), have been noted in the safety profile.


Q: Are there any major diet changes required while on Atorvastatin MS?

A: Official documents specify constraints regarding the consumption of large quantities of grapefruit juice and note the risk associated with substantial alcohol consumption. Apart from these specific constraints, other general diet changes are not detailed or mandated within the official drug label information.


Q: Is it true that grapefruit juice can affect Atorvastatin MS?

A: Yes, grapefruit juice can affect the medicine. According to official labeling, it can increase the amount of Atorvastatin that enters the bloodstream (known as plasma concentration). The constraint is specifically documented regarding the consumption of large quantities (e.g., more than 1.2 liters daily).


Q: What is the general timeline for Atorvastatin MS to start working?

A: Research examining the medicine for elevated cholesterol typically tracks changes in lipid markers, such as LDL-C, over observation periods generally lasting up to one year. This timeline reflects when the effects on blood biomarkers are measured in clinical studies.


Q: Does Atorvastatin MS have an effect on liver health?

A: Yes. The medicine is formally contraindicated (must not be used) in patients who currently have active liver disease or unexplained, persistently elevated liver enzymes. Hepatic failure (liver failure) is also documented as a rare, serious adverse reaction.


Q: Is Atorvastatin MS associated with changes in sleep patterns?

A: Yes, regulatory documents note that changes in sleep patterns have been reported with statin use. These documented sleep disturbances include instances of insomnia and nightmares.


Q: Does Atorvastatin MS cause weight gain?

A: Increased weight has been noted in postmarketing reports compiled from real-world use of the medicine. The frequency with which this occurs, however, is reported as unknown.


Q: Is Atorvastatin MS used to prevent heart attacks?

A: Yes. The medicine is used for the primary and secondary prevention of major cardiovascular events, which includes the prevention of nonfatal heart attacks and strokes. This use is supported by results from large clinical trials.


Q: What is the difference between Atorvastatin MS and other 'statin' drugs?

A: Atorvastatin is described as a potent statin with a distinct synthetic structure. It is clinically recognized for its ability to achieve significant reductions in Low-Density Lipoprotein Cholesterol (LDL-C) levels, making it one of the more potent agents in the statin class.


Q: What are the most commonly reported side effects of Atorvastatin MS?

A: Common effects, meaning they occur in 1 to 10 out of 100 people, include nasopharyngitis (common cold symptoms) and headache. Other common effects involve muscle and joint discomfort, such as myalgia (muscle pain) and arthralgia (joint pain), along with certain gastrointestinal issues.


Q: Is it possible to have an allergic reaction to Atorvastatin MS?

A: Yes. According to the official patient eligibility guidelines, use is formally prohibited for any patient with a known hypersensitivity to atorvastatin. Hypersensitivity describes an adverse immune response, which includes allergic reactions.


Q: Is Atorvastatin MS a blood thinner?

A: No. Atorvastatin is classified as a statin, belonging to the pharmacological category of HMG-CoA reductase inhibitors. Its primary therapeutic purpose is to manage high levels of lipids (cholesterol) in the bloodstream, not to thin the blood.


Q: What are the official guidelines regarding the use of Atorvastatin MS in patients with liver problems?

A: Use is contraindicated, or prohibited, in patients with active liver disease or unexplained persistent elevations of liver enzymes. For individuals who have a history of liver problems, special caution is required during treatment, as noted in the eligibility guidelines.


Q: Are there any known interactions between Atorvastatin MS and herbal supplements?

A: Yes, the herbal remedy St. John's wort is documented to potentially reduce the effectiveness of Atorvastatin. The official patient information typically suggests that individuals discuss all supplement information, including herbal remedies, with their healthcare provider.


Q: Can Atorvastatin MS interact with common pain relievers?

A: Yes, an increased risk of muscle toxicity is officially documented when Atorvastatin is co-administered with Colchicine. Colchicine is a medication used to treat pain and inflammation related to gout.


Q: Does Atorvastatin MS affect blood sugar levels?

A: Regulatory safety information notes that individuals with diabetes are a risk factor for certain adverse events. Additionally, changes in glucose metabolism have been associated with statin use.


Q: Is Atorvastatin MS used in people without high cholesterol?

A: Yes, the medicine is used for the primary prevention of cardiovascular events in adults who have certain risk factors, such as high blood pressure or Type 2 Diabetes. This includes use in populations who have not yet had a heart attack or stroke.


Q: Is there a link between Atorvastatin MS and memory issues?

A: Yes, cognitive impairment, which includes reports of forgetfulness or memory loss and confusion, has been noted with all statins. These effects are reported rarely and are generally described as reversible.


Q: How quickly does the effect of Atorvastatin MS disappear if discontinued?

A: While the exact time frame for the disappearance of the therapeutic effect is not specified in the patient label, research indicates that drug-associated biological changes, such as elevated liver enzymes, generally return to baseline levels within weeks of discontinuation.


Q: Can Atorvastatin MS interact with vitamins?

A: There are currently no reports of Atorvastatin interacting with general vitamins based on official safety information. The official patient information typically suggests that individuals share all supplement and vitamin information with their healthcare provider.


Q: Is Atorvastatin MS considered a preventive medicine?

A: Yes, the medicine is formally used for both primary and secondary prevention of cardiovascular events in at-risk populations. This means it is used to lower the risk of future serious events like heart attacks and strokes.


Q: Is Atorvastatin MS intended to be a lifelong treatment?

A: Official information describes the drug as being intended for once-daily intake as part of a long-term therapeutic protocol. This reflects its use in managing cardiovascular risk factors, which typically requires ongoing management.


Q: Can Atorvastatin MS cause dizziness?

A: Yes, reports of dizziness have been noted in postmarketing safety data. The frequency of this side effect is reported as unknown based on the clinical trial results.


Q: Is there a known interaction between Atorvastatin MS and antibiotics?

A: Yes, an interaction is known. Certain antibiotics (such as erythromycin and clarithromycin) are known to inhibit the CYP3A4 enzyme system. This effect can significantly increase Atorvastatin plasma concentrations (exposure).


Q: Can Atorvastatin MS be used with blood pressure medication?

A: Research on the medicine included study participants who had established cardiovascular risk factors, such as high blood pressure. This indicates that co-use with blood pressure medications was observed in the studied populations.


Q: What does 'primary prevention' mean in the context of Atorvastatin MS?

A: Primary prevention is the use of the medicine in adults who have cardiovascular risk factors (like high blood pressure or Type 2 Diabetes) but who have not yet experienced a heart attack or stroke. It is used to reduce the likelihood of a first event.

How should Atorvastatin MS be stored and disposed of?

How to Store and Dispose of Atorvastatin MS

Atorvastatin MS tablets must be stored at Controlled Room Temperature (CRT), maintained between 20°C and 25°C (68°F and 77°F). Brief temperature excursions are permitted between 15°C and 30°C (59°F and 86°F).

Storage Requirements

Constraint Requirement
Temperature CRT: 20°C to 25°C
Protection Keep in original container and protect from moisture
Safety Store out of the reach of children

Disposal

Unused or expired Atorvastatin MS must be disposed of according to local requirements. The recommended official procedure is to utilize a drug take-back program. If this option is unavailable, the medication should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Do not flush the tablets down a toilet or pour them down a drain unless specifically instructed by a governmental agency.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atorvastatin MS found in:

A-Z Index: